Nestorone®: A progestin with a unique pharmacological profile

Steroids

Volumn 65, Issue 10-11, 2000, Pages 629-636

  Kumar, Narender ^a   Koide, Samuel S ^a   Tsong, Yun Yen ^a   Sundaram, Kalyan ^a  

^a POPULATION COUNCIL   (United States)

Author keywords

Androgenic activity; Pharmacology; Progestin

Indexed keywords

ANDROGEN RECEPTOR; DESOGESTREL; ELCOMETRINE; ESTROGEN RECEPTOR; ETONOGESTREL; GLUCOCORTICOID RECEPTOR; LEVONORGESTREL; PROGESTERONE; PROGESTERONE RECEPTOR; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; CONTRACEPTIVE AGENT; PROGESTERONE DERIVATIVE; STEROID RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; CASTRATION; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; FEMALE; HORMONE ACTION; LEVATOR ANI MUSCLE; MALE; NONHUMAN; OVULATION INHIBITION; PREGNANCY; PROSTATE VENTRAL LOBE; RABBIT; RAT; ANIMAL; ARTICLE; BINDING COMPETITION; COMPARATIVE STUDY; ENDOMETRIUM; METABOLISM; ORGAN SIZE; OVULATION; PHYSIOLOGY; PROSTATE; PROTEIN BINDING; SPRAGUE DAWLEY RAT;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

ANIMALS; BINDING, COMPETITIVE; CONTRACEPTIVE AGENTS, FEMALE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIUM; FEMALE; MALE; NORPROGESTERONES; ORGAN SIZE; OVULATION; PREGNANCY; PREGNANCY MAINTENANCE; PROGESTERONE CONGENERS; PROSTATE; PROTEIN BINDING; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; RECEPTORS, GLUCOCORTICOID; RECEPTORS, PROGESTERONE; RECEPTORS, STEROID; TESTOSTERONE;

EID: 0033623603     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(00)00119-7     Document Type: Conference Paper

References (36)

1. Selectivity information on desogestrel
2. Comparative pharmacology of newer progestogens
3. Clinical trial with Nestorone® subdermal contraceptive implants
4. Milk and plasma concentrations of the progestin ST 1435 in women treated parenterally with ST 1435
5. Fertility control with subdermal silastic capsules containing a new progestin (ST 1435)
6. Contraception with subdermal implants releasing the progestin ST 1435: A dose-finding study
7. Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing ST 1435
8. Contraception with subdermal ST 1435 capsules: Side-effects, endocrine profiles and liver function related to different lengths of capsules
9. Serum lipids, blood pressure, body weight, and serum chemistry in women using s.c. contraceptive implants releasing the progestin ST 1435
10. Aromatization of 7 α-methyl-19-nortestosterone by human placental microsomes in vitro
11. Nuclear androgen receptors in the mouse kidney: Validation of a new assay
12. Pharmacokinetics of 7 α-methyl-19-nortestosterone in men and cynomologus monkeys
13. The assay of progestin
14. A colorimetric micromethod for the determination of glycogen in tissues
15. Corticoid mediated increase in tyrosine α-ketoglutarate transaminase in the rat. A sensitive glucocorticoid assay
16. Evaluation of four different contraceptive vaginal rings: Steroid serum levels, luteal activity, bleeding control, and lipid profiles
17. Transdermal application of steroid hormones for contraception
18. Sustained release contraceptives
19. Metabolic changes during treatment with two different progestogens
20. Effects of different doses of norethisterone on ovarian function, serum sex hormone binding globulin and high density lipoprotein-cholesterol
21. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity
22. FDA requirements for nonclinical testing of contraceptive steroids
23. High density lipoprotein as a protective factor against heart disease
24. Lipid metabolic studies in oophorectomized women: Effects of three different progestagens
25. A comparison of the potencies and activities of progestagens used in contraceptives
26. Binding of progestogens to receptor proteins in MCF-7 cells
27. Progestational and androgenic receptor binding affinities and in vitro activities of norgestimate and other progestins
28. The androgenicity of progestins
29. Serum non-protein bound percentage and distribution of the progestin ST-1435: No effect of ST-1435 treatment on plasma SHBG and CBG binding capacities
30. Transport of steroid hormones: Binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma
31. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation
32. Norgestrel and gestodene stimulate breast cancer cell growth through an estrogen receptor mediated mechanism
33. Estrogenic and progestational activity of 7 α-methyl-19-nortestosterone, a synthetic androgen
34. Progestin binds to the glucocorticoid receptor and mediates antiglucocorticoid effect in rat adipose precursor cells
35. Effects of progestin administration on the hypothalamic-pituitary-adrenal axis and glucose homeostasis in dogs
36. The progestin ST-1435 - Rapid metabolism in man